130 related articles for article (PubMed ID: 15467440)
1. The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.
Sun SY; Zhou Z; Wang R; Fu H; Khuri FR
Cancer Biol Ther; 2004 Nov; 3(11):1092-8; discussion 1099-1101. PubMed ID: 15467440
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase inhibition: who are the Aktors?
Bernhard EJ
Cancer Biol Ther; 2004 Nov; 3(11):1099-101. PubMed ID: 15640614
[No Abstract] [Full Text] [Related]
3. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.
Han JY; Oh SH; Morgillo F; Myers JN; Kim E; Hong WK; Lee HY
J Natl Cancer Inst; 2005 Sep; 97(17):1272-86. PubMed ID: 16145048
[TBL] [Abstract][Full Text] [Related]
6. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
[TBL] [Abstract][Full Text] [Related]
7. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
Smalley KS; Eisen TG
Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
[TBL] [Abstract][Full Text] [Related]
8. The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.
Sun SY; Liu X; Zou W; Yue P; Marcus AI; Khuri FR
J Biol Chem; 2007 Jun; 282(26):18800-9. PubMed ID: 17493934
[TBL] [Abstract][Full Text] [Related]
9. Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors.
Du W; Liu A; Prendergast GC
Cancer Res; 1999 Sep; 59(17):4208-12. PubMed ID: 10485456
[TBL] [Abstract][Full Text] [Related]
10. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
David E; Sun SY; Waller EK; Chen J; Khuri FR; Lonial S
Blood; 2005 Dec; 106(13):4322-9. PubMed ID: 16118318
[TBL] [Abstract][Full Text] [Related]
11. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells.
Chun KH; Lee HY; Hassan K; Khuri F; Hong WK; Lotan R
Cancer Res; 2003 Aug; 63(16):4796-800. PubMed ID: 12941797
[TBL] [Abstract][Full Text] [Related]
12. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis.
Jiang K; Coppola D; Crespo NC; Nicosia SV; Hamilton AD; Sebti SM; Cheng JQ
Mol Cell Biol; 2000 Jan; 20(1):139-48. PubMed ID: 10594016
[TBL] [Abstract][Full Text] [Related]
13. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Liu G; Marrinan CH; Taylor SA; Black S; Basso AD; Kirschmeier P; Robert Bishop W; Liu M; Long BJ
Anticancer Drugs; 2007 Sep; 18(8):923-31. PubMed ID: 17667598
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Kim ES; Kies MS; Fossella FV; Glisson BS; Zaknoen S; Statkevich P; Munden RF; Summey C; Pisters KM; Papadimitrakopoulou V; Tighiouart M; Rogatko A; Khuri FR
Cancer; 2005 Aug; 104(3):561-9. PubMed ID: 16028213
[TBL] [Abstract][Full Text] [Related]
16. Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.
Zheng H; Liu A; Liu B; Li M; Yu H; Luo X
Cancer Lett; 2010 Nov; 297(1):117-25. PubMed ID: 20554106
[TBL] [Abstract][Full Text] [Related]
17. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.
Brognard J; Clark AS; Ni Y; Dennis PA
Cancer Res; 2001 May; 61(10):3986-97. PubMed ID: 11358816
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
19. Akt-dependent antiapoptotic action of insulin is sensitive to farnesyltransferase inhibitor.
Park D; Pandey SK; Maksimova E; Kole S; Bernier M
Biochemistry; 2000 Oct; 39(41):12513-21. PubMed ID: 11027130
[TBL] [Abstract][Full Text] [Related]
20. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]